...
首页> 外文期刊>Journal of the Indian Medical Association. >Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
【24h】

Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.

机译:接受大手术的2型糖尿病患者的血糖控制:三种皮下胰岛素治疗方案的比较。

获取原文
获取原文并翻译 | 示例

摘要

Pre-operative glucose control with subcutaneous insulin in non-urgent situations is logical and well accepted. But the best regimen amongst the many available ones of insulin administration during peroperative period during major surgery is uncertain. We compared three subcutaneous insulin regimens for pre-operative glucose control in type 2 diabetes mellitus (T2DM) patients. One hundred and seventy-two T2DM patients hospitalised for major surgeries were enrolled in the study. Pre-operative glycaemic control was achieved with one of the following regimens: (1) Premix 30/70 insulin (R/N-0-R/N). (2) R + NPH; basal-bolus regular and NPH insulin (R-R-R/N). (3) R + G; basal-bolus regular and glargine insulin (R-R-R-G) [G: glargine insulin; N: neutral protamine hagedorn insulin; R: regular insulin]. Insulin doses were adjusted to achieve fasting and postmeal glucose values respectively <120 and <180 mg/dl. Intra-operative management included glucose insulin potassium solution. Postoperatively, patients were switched back to the same insulin regimen that they received pre-operatively. These regimens were compared for following parameters. (1) Time to achieve glycaemic target. (2) Total daily insulin dose. (3) Incidence of hypo- and severe hyperglycaemia. (4) Complications like renal failure, infection, etc. (5) in hospital mortality. R + G regimen was associated with lesser dose of insulin (29.53 +/- 9.83 versus 35.67 +/- 12.19 and 37.42 +/- 13.5 unit respectively for regimen 2 and 1, p < 0.005), lesser time to achieve glycaemic target (6.75 +/- 3.25 versus 7.37 +/- 7.47 and 8.23 +/- 6.04 days, p > 0.05), lower incidence of hypoglycaemia (10.53 versus 14.81 and 30.00%, p < 0.02) and severe hyperglycaemia (5.26 versus 29.63 and 8.33%, p < 0.005). Incidence of infection (10.53 versus 18.52 and 15.00%, p > 0.05), renal complications (10.53 versus 11.11 and 15.00%, p > 0.05) and mortality (5.26 versus 14.81 and 15.00%, p > 0.05) were lower with this regimen, but the difference was not statistically significant. Premix 30/70 and R + NPH regimens were comparable for most parameters but hypoglycaemia and severe hyperglycaemia were more frequent respectively with premix 30/70 and R + NPH regimens. In contrast to the popular perception about the risk of hypoglycaemia with long acting insulins, insulin analogue glargine was found to be better than NPH insulin in basal bolus regimens in achieving better glycaemic control with fewer incidence of hypoglycaemia.
机译:在非紧急情况下用皮下胰岛素进行术前血糖控制是合乎逻辑的,并且被广泛接受。但是,在大手术过程中,在围手术期胰岛素可用的众多最佳方案中,尚无定论。我们比较了2种2型糖尿病(T2DM)患者术前血糖控制的三种皮下胰岛素治疗方案。该研究纳入了因大手术而住院的172名T2DM患者。术前血糖控制通过以下方案之一实现:(1)预混30/70胰岛素(R / N-0-R / N)。 (2)R + NPH;基础推注常规和NPH胰岛素(R-R-R / N)。 (3)R + G;基础推注常规和甘精胰岛素(R-R-R-G)[G:甘精胰岛素; N:中性鱼精蛋白苦参素胰岛素; R:普通胰岛素]。调节胰岛素剂量以分别达到空腹和餐后葡萄糖值<120和<180 mg / dl。术中管理包括葡萄糖,胰岛素,钾溶液。术后,患者转回与术前相同的胰岛素治疗方案。比较这些方案的以下参数。 (1)达到血糖目标的时间。 (2)每日总胰岛素剂量。 (3)低血糖和严重高血糖的发生率。 (4)并发症,例如肾衰竭,感染等。(5)医院死亡率。 R + G方案与较少剂量的胰岛素相关(方案2和方案1分别为29.53 +/- 9.83和35.67 +/- 12.19和37.42 +/- 13.5单位,p <0.005),达到血糖目标的时间更短(6.75) +/- 3.25与7.37 +/- 7.47和8.23 +/- 6.04天,p> 0.05),低血糖发生率较低(10.53对14.81和30.00%,p <0.02)和严重高血糖(5.26对29.63和8.33%, p <0.005)。在这种方案下,感染发生率(10.53对18.52和15.00%,p> 0.05),肾脏并发症(10.53对11.11和15.00%,p> 0.05)和死亡率(5.26对14.81和15.00%,p> 0.05)较低,但差异无统计学意义。对于大多数参数,预混30/70和R + NPH方案相当,但预混30/70和R + NPH方案分别降低低血糖和严重高血糖。与普遍认为长效胰岛素具有降低血糖风险的观点相反,在基础推注方案中,胰岛素类似物甘精胰岛素优于NPH胰岛素,可实现更好的血糖控制,降低低血糖发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号